Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
It found that signals for IOHs were present for both monotherapies and many combination therapies, with the highest risk occurring within the first 90 days of treatment.
Full summary
861 CHARS
It compared reporting odds ratios (RORs) and information components (ICs) for IOHs under monotherapy and combination therapy. Signals were detected for monotherapy with aspirin, clopidogrel, warfarin, apixaban, and rivaroxaban, and for several combination therapies including dual antiplatelet therapy (DAPT). Subgroup analyses indicated IOH signals were more frequent in younger patients on aspirin and elderly patients on warfarin. Time-to-onset analysis for monotherapies suggested a median occurrence within 90 days. Limitations include the passive, voluntary reporting nature of the JADER database, potential for under-reporting, confounding by comorbidities like hypertension and diabetes, lack of dose information, and small case numbers for some drugs. The findings highlight the need for clinical awareness of potential IOH risk with these medications.
